213 related articles for article (PubMed ID: 37646208)
1. New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT.
King JB; Berchie RO; Derington CG; Marcum ZA; Scharfstein DO; Greene TH; Herrick JS; Jacobs JA; Zheutlin AR; Bress AP; Cohen JB
J Am Heart Assoc; 2023 Sep; 12(17):e030311. PubMed ID: 37646208
[TBL] [Abstract][Full Text] [Related]
2. Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
Cohen JB; Marcum ZA; Zhang C; Derington CG; Greene TH; Ghazi L; Herrick JS; King JB; Cheung AK; Bryan N; Supiano MA; Sonnen JA; Weintraub WS; Scharfstein D; Williamson J; Pajewski NM; Bress AP;
JAMA Netw Open; 2022 Jul; 5(7):e2220680. PubMed ID: 35834254
[TBL] [Abstract][Full Text] [Related]
3. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Chang TI; Winkelmayer WC
Nephrol Dial Transplant; 2017 May; 32(5):862-869. PubMed ID: 27190342
[TBL] [Abstract][Full Text] [Related]
6. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
Zhang L; Zeng X; Fu P; Wu HM
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
[TBL] [Abstract][Full Text] [Related]
13. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
15. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH; Hall AS
Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
[TBL] [Abstract][Full Text] [Related]
17. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]